Patent Cap in Drug Pricing Bill Seen as Having Muted Effect
July 25, 2024
By: Ryan Davis
Law360
Axinn partner Ted Mathias was quoted in the Law360 article, "Patent Cap in Drug Pricing Bill Seen as Having Muted Effect."
Click here to access the publication, a subscription is required.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Stakeholders 24th Annual CYOC Career Development Conference
Sponsorship
CompLaw 33rd Annual Advanced EU Brussels Conference
Speaking Engagement
ALM General Counsel Conference East 2024
Speaking Engagement
Antitrust
Global Legal Group Global Class Actions Symposium 2024
Speaking Engagement
Litigation & Trials
NAPABA Convention 2024
Sponsorship
Kisaco Research Pharma and Biotech Patent Litigation 2024
Speaking Engagement
Intellectual Property
AIJA IP/TMT Seminar // 11th Antitrust Annual Conference
Speaking Engagement
Antitrust
EDTX Bench Bar Conference 2024
Sponsorship
Antitrust
Informa Connect Antitrust Texas Conference 2024
Speaking Engagement
Antitrust
LSPN North America Fall Conference 2024
Speaking Engagement
Intellectual Property